In this study researchers want to find out if the study drug, called RLY-2608, can help children, teenagers, and adults with overgrowth or malformations caused by PIK3CA mutation. The goal of the study is to find out how well the study drug works and what is the best and safest amount to give to children and teenagers of different ages to treat overgrowth or malformations caused by PIK3CA mutation.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Alexandra Borst
Pediatrics - Children's Research Institute
Clinical or Medical
Interventional
Genetics and Genetic Disorders
25-1109
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
